Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261432444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 09.03.2026. Verfasst von Yanan Zong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Coagulation Research, Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hemophilia A, Extracellular Vesicles, Coronary Artery Disease, Heart Diseases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Patients with hemophilia A (HA) can reach normal life expectancy and suffer from coronary artery disease (CAD). The study evaluates the likelihood of subclinical CAD evaluated by advanced electrocardiography (A-ECG), global hemostasis and extracellular vesicles (EVs) in Chinese patients with HA treated on-demand. Materials and Methods Patients with HA (n = 42) and age-matched male controls (n = 37) were included. The likelihood of having CAD was evaluated by A-ECG. Fibrin formation and fibrinolysis were assessed by the overall hemostatic potential (OHP) assay. EVs derived from platelets (PEVs), endothelial cells (EEVs) and leukocytes (LEVs), and expressing phosphatidylserine (PS + EVs), tissue factor (TF + EVs) or P-selectin (CD62P + EVs) were measured by flow cytometry.
Results
The likelihood of CAD evaluated by A-ECG did not differ between patients and controls. Fibrin formation and clot stability were significantly impaired in patients. Patients had higher PEVs and CD62P + EVs. CD62P + EVs counts were inversely correlated with OHP, velocity and clot lysis time. Subclinical CAD did not correlate with OHP or EVs.
Conclusion
Controls and patients with HA treated on-demand exhibited no differences in A-ECG, but varied in fibrin formation and clot stability. Larger studies are required to explore the significance of this finding in the context of CAD risk in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Coagulation Research, Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Physiology, Karolinska Institutet, Stockholm, Sweden.
- Nicollier-Schlegel SARL, Trelex, Switzerland.
- Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia.
- Clinical Chemistry, Karolinska University Laboratory, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Todd T Schlegel, Apostolos Taxiarchis, Roza Chaireti
Zitieren
APA
Zong, Y., Maanja, M., Schlegel, T. T., Ugander, M., Antovic, J., Taxiarchis, A., Chaireti, R., & Kong, X. (2026). Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261432444
Vancouver
Zong Y, Maanja M, Schlegel TT, Ugander M, Antovic J, Taxiarchis A, et al. Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261432444
BibTeX
@article{Zong2026,
author = {Zong, Yanan and Maanja, Maren and Schlegel, Todd T and Ugander, Martin and Antovic, Jovan and Taxiarchis, Apostolos and Chaireti, Roza and Kong, Xiangdong},
title = {Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261432444}
}
EUVIMED